Cargando…
Randomized comparison of single dose of recombinant human IL-12 versus placebo for restoration of hematopoiesis and improved survival in rhesus monkeys exposed to lethal radiation
BACKGROUND: The hematopoietic syndrome of the acute radiation syndrome (HSARS) is a life-threatening condition in humans exposed to total body irradiation (TBI); no drugs are approved for treating this condition. Recombinant human interleukin-12 (rHuIL-12) is being developed for HSARS mitigation und...
Autores principales: | Gluzman-Poltorak, Zoya, Mendonca, Sarita R, Vainstein, Vladimir, Kha, Hue, Basile, Lena A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4108131/ https://www.ncbi.nlm.nih.gov/pubmed/24708888 http://dx.doi.org/10.1186/1756-8722-7-31 |
Ejemplares similares
-
Gene expression changes in male and female rhesus macaque 60 days after irradiation
por: Majewski, Matthäus, et al.
Publicado: (2021) -
What's new in IL-12? Combination!
por: Lawrence, Chris E, et al.
Publicado: (2015) -
Single low-dose rHuIL-12 safely triggers multilineage hematopoietic and immune-mediated effects
por: Gokhale, Mamata S, et al.
Publicado: (2014) -
HemaMax™, a Recombinant Human Interleukin-12, Is a Potent Mitigator of Acute Radiation Injury in Mice and Non-Human Primates
por: Basile, Lena A., et al.
Publicado: (2012) -
Remdesivir is efficacious in rhesus monkeys exposed to aerosolized Ebola virus
por: Warren, Travis K., et al.
Publicado: (2021)